FTC challenges Amgen’s Enbrel patent strategy, the long, winding path for the Moderna-Merck cancer vaccine, and more biotech news Adobe Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. This morning, we take an inside look at how Moderna and Merck’s cancer vaccine gamble finally paid off, the FTC takes aim at Amgen’s Enbrel patent strategy, and there’s new proto-FDA guidance for generative AI devices. Soundtrack for this Readout: Inferno, by Boards of Canada. Yes, it’s weird. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Meghana Keshavan covers biotech and contributes to The Readout newsletter.
STAT+: Lady Gaga and her fiancé launch a biotech startup
Full Article
Original Source
Read the full article at Statnews →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.